NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)

NCT06079333 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Anaplastic Thyroid Cancer

Interventions

DRUG: dabrafenib/trametinib

Sponsor

Leiden University Medical Center

Collaborators

[object Object]